Cut-off values of immunological tests to identify patients at high risk of severe lupus nephritis

Medicina (B Aires). 2018;78(5):329-335.

Abstract

Cut-off values for anti-dsDNA, anti-nucleosome and anti-C1q antibodies tests and for complementmediated hemolytic activity (CH50) were explored to identify patients with high risk of developing severe lupus nephritis (LN). Forty-one patients with confirmed systemic lupus erythematosus (SLE) were identified; their levels for the three antibodies and complement had been measured on a same serum sample. These patients were classified based on the presence of renal involvem ent; sixteen had active proliferative LN. With the cut-off values accepted in the laboratory for SLE diagnosis (anti-dsDNA > 100 UI/ml, anti-nucleosome > 50 U/ml or CH50 < 190 UCH50%) no significant differences were found between patients with and without LN. Anti-C1q > 40 U/ml showed a statistically significant association with LN and had 80% of specificity. Cut-off values for LN identified by Receiver Operating Characteristic curves (ROC) were higher for anti-dsDNA (> 455 IU/ml) and antinucleosome (>107 U/ml), lower for CH50 (< 150 UCH50%) and, for anti-C1q (> 41 U/ml) coincided with the cut-off values accepted for SLE. Anti-C1q > 134 U/ml had a 92% of specificity, 56% of sensibility and was associated with a fifteen-fold increased risk of LN. The simultaneous presence of anti-nucleosome > 107 U/ml and anti-C1q > 134 U/ml was associated with a 27-fold higher probability for LN. According to these results, the cut-off values used to detect SLE activity could be inadequate to identify patients at high risk of severe LN.

Keywords: immunologic tests; lupus nephritis; systemic lupus erythematosus.

MeSH terms

  • Adolescent
  • Adult
  • Antibodies, Antinuclear / blood
  • Biomarkers / blood
  • Child
  • Child, Preschool
  • Complement C1q / immunology
  • Complement Hemolytic Activity Assay / methods
  • Complement Hemolytic Activity Assay / standards
  • Female
  • Humans
  • Immunologic Tests / methods
  • Immunologic Tests / standards*
  • Infant
  • Lupus Erythematosus, Systemic / blood
  • Lupus Erythematosus, Systemic / diagnosis
  • Lupus Erythematosus, Systemic / immunology
  • Lupus Nephritis / blood*
  • Lupus Nephritis / diagnosis*
  • Lupus Nephritis / immunology
  • Male
  • Middle Aged
  • Nucleosomes / immunology
  • Reference Standards
  • Retrospective Studies
  • Risk Assessment / methods
  • Risk Factors
  • Sensitivity and Specificity
  • Severity of Illness Index
  • Young Adult

Substances

  • Antibodies, Antinuclear
  • Biomarkers
  • Nucleosomes
  • Complement C1q